These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7990345)

  • 21. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A; Karádi I; Köszegi G; Pados G; Németh-Csóka M; Pichler M; Romics L
    Klin Wochenschr; 1990; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract]   [Full Text] [Related]  

  • 24. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass. Effect on blood lipids and apolipoproteins.
    Nessim SA; Chin HP; Alaupovic P; Blankenhorn DH
    Arteriosclerosis; 1983; 3(6):568-73. PubMed ID: 6651612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia].
    Chojnowska-Jezierska J; Adamska-Dyniewska H
    Pol Arch Med Wewn; 1997 Nov; 98(11):391-9. PubMed ID: 9594556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasma exchange therapy in a patient with familial hypercholesteremia and generalized arteriosclerosis].
    Schrecker O; Thies K; Schlierf G
    Internist (Berl); 1984 Sep; 25(9):574-6. PubMed ID: 6386739
    [No Abstract]   [Full Text] [Related]  

  • 28. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.
    Hoeg JM; Maher MB; Bou E; Zech LA; Bailey KR; Gregg RE; Sprecher DL; Susser JK; Pikus AM; Brewer HB
    Circulation; 1984 Dec; 70(6):1004-11. PubMed ID: 6388897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotinic acid for the treatment of hyperlipoproteinemia.
    Drood JM; Zimetbaum PJ; Frishman WH
    J Clin Pharmacol; 1991 Jul; 31(7):641-50. PubMed ID: 1894760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
    Steger W
    Fortschr Med; 1980 May; 98(18):(718-20). PubMed ID: 7390386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Familial hypercholesterolemia: clinical aspects].
    Ciarrocchi A; Gaddi A; Rimondi S; Mezzetti M; Scaramuzzino G
    Cardiologia; 1988 Nov; 33(11):1055-60. PubMed ID: 3255492
    [No Abstract]   [Full Text] [Related]  

  • 33. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.
    Vacek JL; Dittmeier G; Chiarelli T; White J; Bell HH
    Am J Cardiol; 1995 Jul; 76(3):182-4. PubMed ID: 7611158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia.
    Lowe GD; Drummond MM; Third JL; Bremner WF; Forbes CD; Prentice CR; Lawrie TD
    Thromb Haemost; 1980 Feb; 42(5):1503-7. PubMed ID: 7368154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative effects of probucol and placebo on blood cholesterol in patients on long-term treatment (author's transl)].
    Mc Caughan D
    Nouv Presse Med; 1980 Oct; 9(40):3018-20. PubMed ID: 7443444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
    Korkushko OV; Bogatskaia LN; Kovalenko AN; Novikova SN; Kotko DN
    Vrach Delo; 1989 Aug; (8):19-22. PubMed ID: 2588515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of lipid-lowering diets on patients with hyperlipoproteinemia.
    Gustafsson IB; Vessby B; Boberg J; Karlström B; Lithell H
    J Am Diet Assoc; 1982 May; 80(5):426-32. PubMed ID: 7076998
    [No Abstract]   [Full Text] [Related]  

  • 40. "Essential" phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease.
    Klimov AN; Konstantinov VO; Lipovetsky BM; Kuznetsov AS; Lozovsky VT; Trufanov VF; Plavinsky SL; Gundermann KJ; Schumacher R
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):779-84. PubMed ID: 8850382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.